Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Update

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 24,713 shares, a decrease of 61.8% from the August 31st total of 64,641 shares. Based on an average daily volume of 20,204 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.5% of the shares of the stock are sold short.

Neuphoria Therapeutics Trading Down 2.2%

Shares of NASDAQ:NEUP traded down $0.08 during mid-day trading on Tuesday, reaching $3.57. The stock had a trading volume of 14,984 shares, compared to its average volume of 95,083. The business’s 50 day moving average price is $3.79 and its 200 day moving average price is $4.28. Neuphoria Therapeutics has a 1 year low of $3.19 and a 1 year high of $21.40. The company has a market cap of $19.31 million, a P/E ratio of -0.57 and a beta of 0.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Merck & Co. Inc. bought a new stake in shares of Neuphoria Therapeutics in the 2nd quarter valued at approximately $43,818. AdvisorShares Investments LLC raised its position in Neuphoria Therapeutics by 15.8% in the 1st quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock worth $632,000 after purchasing an additional 21,173 shares during the period. Finally, ADAR1 Capital Management LLC bought a new stake in Neuphoria Therapeutics in the second quarter worth about $131,000. 15.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NEUP has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Neuphoria Therapeutics to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, August 27th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $7.00.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and other metabolic diseases. The company’s research programs are designed to address conditions involving weight management, diabetes and metabolic dysfunction.

Neuphoria’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed for obesity and related metabolic conditions. The company is also developing DA-1241, an investigational GPR119 agonist intended for metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis, and other metabolic disorders.